Acute Myeloid Leukemia (AML) Overview

Save information for later
Sign Up

Learn About Acute Myeloid Leukemia (AML)

View Main Condition: Leukemia

What is the definition of Acute Myeloid Leukemia (AML)?
Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inherited syndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor.
Who are the top Acute Myeloid Leukemia (AML) Local Doctors?
Marcos J. De Lima
Elite in Acute Myeloid Leukemia (AML)
Dr. Marcos J. De Lima
Hematology Oncology | Oncology | Hematology
Elite in Acute Myeloid Leukemia (AML)
Dr. Marcos J. De Lima
Hematology Oncology | Oncology | Hematology

Osu Internal Medicine LLC

410 W 10th Ave, 
Columbus, OH 
614-293-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Marcos De Lima is a Hematologist Oncology specialist and an Oncologist in Columbus, Ohio. Dr. De Lima is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. De Lima is currently accepting new patients.

Stephen J. Forman
Elite in Acute Myeloid Leukemia (AML)
Dr. Stephen J. Forman
Hematology
Elite in Acute Myeloid Leukemia (AML)
Dr. Stephen J. Forman
Hematology

City Of Hope Medical Foundation

1500 Duarte Rd, 
Duarte, CA 
626-256-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Forman is a Hematologist in Duarte, California. Dr. Forman is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

 
 
 
 
Learn about our expert tiers
Learn More
Vijaya R. Bhatt
Elite in Acute Myeloid Leukemia (AML)
Dr. Vijaya R. Bhatt
Hematology Oncology | Hematology | Oncology
Elite in Acute Myeloid Leukemia (AML)
Dr. Vijaya R. Bhatt
Hematology Oncology | Hematology | Oncology

Unmc Physicians

Emile 42nd St, 
Omaha, NE 
402-559-4015
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Vijaya Bhatt is a Hematologist Oncology specialist and a Hematologist in Omaha, Nebraska. Dr. Bhatt is rated as an Elite provider by MediFind in the treatment of Acute Myeloid Leukemia (AML). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bhatt is currently accepting new patients.

View All Doctors
What are the latest Acute Myeloid Leukemia (AML) Clinical Trials?
A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies
A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Biological, Device
Study Phase: Phase 1

Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes. Researchers want to test a method of treating blood cancers by altering a person s T cells (a type of immune cell) to target neoepitopes.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2

Summary: This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the gr...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center